Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy

16Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

Abstract

Cholesterol metabolism is often dysregulated in cancer. Squalene monooxygenase (SQLE) is the second rate-limiting enzyme involved in cholesterol synthesis. Since the discovery of SQLE dysregulation in cancer, compelling evidence has indicated that SQLE plays a vital role in cancer initiation and progression and is a promising therapeutic target for cancer treatment. In this review, we provide an overview of the role and regulation of SQLE in cancer and summarize the updates of antitumor therapy targeting SQLE.

Cite

CITATION STYLE

APA

Zou, Y., Zhang, H., Bi, F., Tang, Q., & Xu, H. (2022, August 24). Targeting the key cholesterol biosynthesis enzyme squalene monooxygenasefor cancer therapy. Frontiers in Oncology. Frontiers Media S.A. https://doi.org/10.3389/fonc.2022.938502

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free